10. Drug-Induced Autoimmune Hepatitis: Systematic Review And Case Study

Authors

  • А.Е. Gainutdin Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • А.V. Nersesov Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • J.А. Kaibullayeva Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • А.М. Raisova Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • Д.С. Сулейменова Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • Н.А. Ашимова Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • N.А. Ashimova Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • A.Е. Kaulybekova Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • N.M. Churukova Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • Sh.А. Kuzbergenova Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan
  • N.Zh. Akmolda Asfendiyarov Kazakh National Medical University, Department of gastroenterology, Almaty, Kazakhstan

DOI:

https://doi.org/10.35805/BSK2023II010

Downloads

Abstract

Drug-induced liver injury (DILI) is one of the types of adverse reactions to drugs that occur as a result of their hepatotoxic effect. The pathogenesis of drug-induced autoimmune hepatitis (LIAH) is based on the production of autoantibodies to neoantigens, which are proteins of the cytochrome P450 system, which are the result of the reaction of drug metabolites. A clinically relevant problem, such as drug-induced liver damage, affects 1-1.5 million patients almost every year. The annual incidence of DILI ranges from 2.3-13.9 per 100,000 population in population studies from Europe. The Icelandic population study recorded the highest rates of 19.1 per 100,000 population per year. And in the only study based on the US population, it was found that DILI is approximately 3 per 100,000 population. Acute hepatitis is currently a well-known manifestation, and accounts for more than 90% of liver damage caused by medications. According to studies, 2.9 - 8.8% of DILI and 2 - 18% of AIH are associated with drug-induced autoimmune hepatitis. The incidence of drug-induced liver damage with the presence of antibodies (antibodies to nuclear antigen, smooth muscle and soluble liver antigen) to AIH is 83% for nitrofurantoin, 74% for minocycline, 60% for methyldopa and 43% for hydralazine.

Keywords

drug induced liver injury, clinical case, RUCAM

References

  1. Tian T. Yeong, Kok H. J. Lim, Stephanie Goubet, Nick Parnell, SumitaVerma. Natural history and outcomes in drug-induced autoimmune hepatitis. 2016 Mar, 46(3):E79-E88
  2. Einar Björnsson, Jayant Talwalkar, Sombat Treeprasertsuk, Patrick S. Kamath, Naoki Takahashi, Schuyler Sanderson, Matthias Neuhauser, Keith Lindor. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. 2010 June;51(6):2040-2048
  3. Kazushi Sugimoto, Takeshi Ito, Norihiko Yamamoto, Katsuya Shiraki. Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology 2011 Nov;54(5):1892-3. doi:10.1002/hep.24513.
  4. Li-Mei Qua, Shu-Hua Wangb, Kun Yanga, David R. Brigstockcd, Li Suna, Run-Ping Gaoa. CD4+Foxp3+CD25+/− Tregs characterize liver tissue specimens of patients suffering from drug-induced autoimmune hepatitis: A clinical-pathological study. Hepatobiliary & Pancreatic Diseases International. Vol.17, 2, Apr 2018, P.133-139
  5. Akiko Hisamochi, Masayoshi Kage, Tatsuya Ide, Teruko Arinaga-Hino, Keisuke Amano, Reiichiro Kuwahara, Kei Ogata, Ichiro Miyajima, Ryukichi Kumashiro, Michio Sata & Takuji Torimura. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. Journal of Gastroenterology 2016, Vol. 51, P.597–607
  6. Thomas D, Wu TY, Cottagiri M, Nyandjo M, Njoku DB. Induction of drug-induced, autoimmune hepatitis in BALB/c Mice for the study of its pathogenic mechanisms. J Vis Exp. 2020 May 29;(159)
  7. Kawabata H, Kawakatsu Y, Inoue N, Okazaki Y, Sone D, Yamaguchi K, Ueda Y, Hitomi M, Miyata M, Motoi S, Enoki Y, Minamikawa T. IgG4-related Autoimmune Hepatitis with a Suspected Drug-induced Etiology. Intern Med. 2020;59(11):1401-1405
  8. Kawasaki E, Fukuyama T, Kuriyama E, Uchida A, Sagara Y, Tamai H, Nakano Y, Tojikubo M, Koga N. Statin-induced autoimmune hepatitis in patients with type 1 diabetes: A report of two cases and literature review. J Diabetes Investig. 2020 Nov;11(6):1673-1676
  9. Alejandra Villamil, Eduardo Mullen, Paola Casciato, Adrian Gadano. Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature. Annals of Hepatology, 2015, 14(2):273-280
  10. Amanda Ricciuto, Binita M. Kamath, Thomas D. Walters, Peter C. Church, Simon C. Ling, Anne M. Griffiths. New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children. 2018 March, 94:128-135.
  11. Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun. 2020 Jan 2;4(2):172-184
  12. Jenkins A, Austin A, Hughes K, Sadowski B, Torres D. Infliximab-induced autoimmune hepatitis. BMJ Case Rep. 2021 May 24;14(5):e239944
  13. Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep. 2020 Jul 21;2(6):100149
  14. Efe C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? Autoimmun Rev. 2013 Jan;12(3):337-9
  15. Nataša Dragutinović, Aleksandra Barać, Goran Stevanović, Irena Đorđić, Bianca Paglietti, Jelena Micić, Ema Aleksić, Jelena Martinov Nestorov. Acute hepatitis in a paediatric patient: immune-mediated drug-induced liver injury or albendazole-induced autoimmune hepatitis? 2022; 16(10):1660-1663
  16. Elizabeth G. Harmon, Randolph McConnie, and Anil Kesavan. Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis 2018 Oct;21(4):347-350
  17. Shah J, Lingiah V, Pyrsopoulos N, Galan M. Acute Liver Injury in a Patient Treated With Rosuvastatin: A Rare Adverse Effect. Gastroenterology Res. 2019 Oct;12(5):263-266
  18. EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology, 2019 Jun;70(6):1222–1261. DRUG-INDUCED AUTOIMMUNE HEPATITIS: SYSTEMATIC REVIEW AND CASE STUDY

Published

2023-05-16

Issue

No. 2 (2023)

Section

Статьи